RNA-protein interactions could lead to new coronavirus drug targets

A recent study led by scientists at the University of California, Riverside and UC San Diego has discovered new potential targets for coronavirus antiviral drugs. By mapping previously unknown interactions between RNA and proteins within the SARS-CoV-2 genome, the researchers identified critical sites involved in the virus's replication and regulation.

These interactions, particularly those involving the RNA-dependent RNA polymerase (RdRp) and nucleocapsid (N) protein, were found to significantly disrupt viral replication when targeted. The findings, published in Nature Communications, suggest that focusing on essential, conserved viral machinery could lead to more effective and resilient antiviral treatments.

Current antiviral drugs like Remdesivir and Paxlovid already target RdRp, highlighting the value of such approaches. The researchers utilized a technique called enhanced cross-linking and immunoprecipitation (eCLIP) to map these interactions across the entire viral genome, revealing unexpected sites, including the N protein's interaction with a conserved region of the viral genome.

This interaction appears to regulate translation, the process by which viral RNA is converted into proteins. Additionally, the study identified a novel interaction between RdRp and the RNA encoding the viral protein NSP3, indicating that viral RNA may have broader regulatory roles than previously understood. The researchers tested the potential of disrupting these sites using antisense oligonucleotides, which successfully reduced viral replication in both monkey cells and human lung cells.

While the work is still in the early stages, with further animal studies needed to confirm therapeutic potential, the findings suggest that targeting conserved viral processes could be a promising strategy for treating multiple coronaviruses with a single drug.